Equity Briefing: Pluristem's PLX Cell Therapy in Failed Bone Marrow Transplant Proven Successful a Second Time

Last month we examined emerging biotech Pluristem Therapeutics (NASDAQ:PSTI), whose cell therapy treats vascular disease with a novel intramuscular injection that restores patency to damaged arteries. ...